Emily Lemke

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

Amishi Y. Shah, Ritesh R. Kotecha, Emily Lemke et al. · European Journal of Cancer · 2019 · 120 citations · Full text

Urology, Genitourinary Cancer, Medicine +4

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Vadim S. Koshkin, Nicholas Henderson, Marihella James et al. · Cancer · 2021 · 80 citations · Full text

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

Matthew T. Campbell, Mehmet Asım Bilen, Amishi Y. Shah et al. · European Journal of Cancer · 2018 · 64 citations

Urology, Surgical Oncology, Oncology +5

Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.

Amanda Nizam, Tanya Jindal, Cindy Jiang et al. · Journal of Clinical Oncology · 2024 · 16 citations

Cancer Management, Clinical Endpoint, Median Time +20

Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.

Amishi Y. Shah, Ritesh R. Kotecha, Emily Lemke et al. · Journal of Clinical Oncology · 2019 · 13 citations